Abbott Laboratories' said on Monday it had received clearance to market the smallest version of its fastest-growing low-cost diabetes monitoring product in the European Union.

Abbott Laboratories is set to report Q3 earnings, with EPS expectations of $1.30, reflecting 8.3% YoY growth. Learn more ...

The US Food and Drug Administration (FDA) has granted de novo classification to Biolinq Shine, a wearable biosensor that would be the first needle-free continuous glucose monitoring (CGM) device to ...

Abbot⁠t Labor‌atories (NYSE​:ABT) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now. Abbot⁠t ...

Abbott’s wide-ranging portfolio, spanning diabetes care, cardiovascular devices, nutritionals, diagnostics, and established ...

That being said, even among dividend stocks, many aren't worth sticking with for the long term. Let's consider one dividend ...

Medical devices continue to be a strong growth driver for Abbott, as the company battles its ongoing sales slump in ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equity markets continued ...

Abbott continues to get a boost in its Medical Devices business from its Diabetes unit's portfolio of continuous glucose ...

From teaming up with the Trump administration to partnering with the Social Security Administration, here is a look at where EHR giant Epic is ...

Abbott eyes 10% EPS growth in 2026 with CGM momentum, new nutrition contracts, and medical device launches driving global ...

On social media, Tandem Diabetes Care (Nasdaq:TNDM) said the launch of a new integration for its insulin pump system is near.